TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Invex Therapeutics Ltd. ( (AU:IXC) ) has issued an announcement.
Invex Therapeutics Limited has responded to a query from the ASX regarding a recent increase in the price and trading volume of its securities. The company was in exclusive negotiations for a potential acquisition of a neurological diseases therapeutics development company, but these talks were discontinued due to concerns over possible changes in the company’s direction and control. Invex confirmed compliance with ASX listing rules and stated that no other undisclosed information could explain the recent trading activity.
More about Invex Therapeutics Ltd.
Invex Therapeutics Limited operates in the biotechnology industry, focusing on the development of therapeutics for neurological diseases. The company is engaged in the research and development of treatments aimed at addressing unmet medical needs in this sector.
Average Trading Volume: 69,125
Technical Sentiment Signal: Buy
Current Market Cap: A$12.02M
Find detailed analytics on IXC stock on TipRanks’ Stock Analysis page.